StockData
Coya Therapeutics, Inc. logo

Coya Therapeutics, Inc. (COYA) company profile

COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3017% above fair value
$3.02+0.02 (+0.67%)

Close on Nov 17, 2026Market cap $70.84MP/E –Yield –

About Coya Therapeutics

Pharmaceutical Preparations, SIC 2834

Coya Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies designed to enhance the function of regulatory T cells, or Tregs. The company explores three therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Its pipeline addresses neurodegenerative, autoimmune, and metabolic diseases, with primary focus on conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Its lead candidate, COYA 302, is a combination biologic utilizing low-dose interleukin-2 alongside a fusion protein. Another candidate, COYA 303, combines low-dose interleukin-2 with a GLP-1 receptor agonist for inflammatory conditions. Because its product candidates remain in clinical and preclinical development, the company does not have commercial customers.

The company operates through strategic research collaborations, licensing agreements, and partnerships, including research work conducted with Houston Methodist Hospital. Its clinical investigations, such as the multicenter ALSTARS Phase 2 trial, take place in the United States. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Coya Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Coya Therapeutics, Inc.
Headquarters
Houston, TX
Address
12645 Memorial Dr., Suite F1 #305 77024
Phone
(650) 739-3939
Employees
8, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Weaver and Tidwell, L.L.P., New York, NY

Stock & identifiers

Ticker
COYA
Exchange
Nasdaq
IPO date
Dec 30, 2022
Shares outstanding
23M, Aug 7, 2026
Public float
$89.42M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1835022
CUSIP
22407B108
ISIN
US22407B1089
FIGI
BBG00Z4HBCB9
Share class FIGI
BBG00Z4HBCC8
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Howard BermanExecutive Chairman, Director949,338
Arun SwaminathanChief Executive Officer, Director10,000
David S. SnyderChief Financial Officer8,800
Fred GrossmanChief Medical Officer2,710
Mark H. PavaoDirector–
Ann LeeDirector33,958
Wilbur L. Ross JrDirector165,016
Dieter WeinandDirector–
Dov A. Goldstein MdDirector27,557
Anabella VillalobosDirector10,000

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Arun Swaminathan
Chief Executive Officer, Director
$546.00K$395.85K$1.15M$2.09M+40%
Howard Berman
Former Chief Executive Officer, Former Executive Chairman of the Board
$436.80K$316.68K$718.22K$1.47M-45%
David Snyder
Chief Financial Officer and Chief Operating Officer
$442.00K$256.36K$670.34K$1.37M-7%
Fred Grossman
President, Chief Medical Officer
$498.16K$288.93K$670.34K$1.46M-23%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 30, 2022
Offer price
$5.00
Securities offered
3,050,000
Gross proceeds
$15.25M
Exchange
Nasdaq
First trading day
Dec 29, 2022
First-day close
$4.57-8.6%
Lock-up ends (est.)
Jun 27, 2023

“Per Share and Accompanying Warrant Total Public offering price $ 5.00 $ 15,250,000 Underwriting discount and commissions ( 1 ) $ 0.35 $ 1,067,500 Proceeds, before expenses, to us ( 2 ) $ 4.65 $ 14,182,500 ( 1 ) Underwriting discounts and commissions do not include the reimbursement of certain expenses of the underwriters we have agreed to”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We have eight full-time employees, and utilize consultants, contract research organizations and third parties to perform our pre-clinical studies, clinical studies, administrative, and financial functions.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?